ArticleMolecular imaging and biology2023
MRI Contrasting Agent Based on Mn-MOF-74 Nanoparticles with Coordinatively Unsaturated Sites.
Article in Molecular imaging and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Advances and Prospects in MOF-Based Platforms for Tumor Hyperthermia.Bioengineering (Basel, Switzerland) · 2026Review
- Metal-Organic Framework as Contrast Agents for Magnetic Resonance Imaging.Pharmaceutics · 2026Review
- Quality Assurance Strategies for Brain State Characterization by MEMRI.bioRxiv : the preprint server for biology · 2026Article
- Cu-based metal-organic frameworks: synthesis, biomedical applications, and beyond.Discover nano · 2026Review
- Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Aqueous-stable Mn(II)-MOF nanoparticles with highJournal of materials chemistry. B · 2025Article
- Metal-Organic Frameworks: Unlocking New Frontiers in Cardiovascular Diagnosis and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Multifunctional metal complex systems emerging from analytical chemistry for theranostic applications.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Review
- Mn-Based MRI Contrast Agents: An Overview.Molecules (Basel, Switzerland) · 2023Review
- Contrast Agents of Magnetic Resonance Imaging and Future Perspective.Nanomaterials (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThe development of magnetic resonance imaging (MRI) contrasting agents (CAs) that are safer and have a higher relaxivity than Gd(III)-based agents is a significant research topic. Herein, we propose the use of a Mn-based metal organic framework (MOF), Mn-MOF-74, characterized by a safe paramagnetic center, a coordinatively unsaturated site (CUS) for aquation, and a long rotational correlation time, endowing high relaxivity. Furthermore, biocompatibility and delivery to the tumor are generally expected for MOFs that are obtainable in the nanometer size range. PROCEDURE: Drop-wise mixing of 2,5-dihydroxyterephthalic acid (DHTP) and Mn(II) acetate yielded Mn-MOF-74 with a diameter of < 150 nm, which was then modified with 1-fivefold higher amounts of poly(ethylene glycol) (M.W. = 5000) to afford MOFs stably dispersed in water for at least 24 h.
resultsThe longitudinal and transverse relaxivity of the PEG-modified MOF was in the range of r
conclusionsThese results suggest that PEG-Mn-MOF-74 can be passively delivered to tumors and can act as a high-relaxivity T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.